[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612744":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":26,"locations":32,"responsibleParty":52,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":10,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"First Affiliated Hospital of Fujian Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"PegIFNα2b+Nucleoside analog",null,"The patients receive both PegIFNα2b and Nucleoside analog therapy.",[13],"Drug: PegIFNα2b+Nucleoside analog",{"label":15,"type":10,"description":16,"interventionNames":17},"PegIFNα2b+Nucleoside analog+Bacteroides fragilis+Branched-Chain Amino Acids","The patients received the concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids, supplemented to their ongoing combination therapy with PegIFNα2b and Nucleoside analog.",[18],"Drug: PegIFNα2b+Nucleoside analog+Bacteroides fragilis+Branched-Chain Amino Acids",[20,23],{"type":21,"name":9,"description":11,"armGroupLabels":22,"otherNames":10},"DRUG",[9],{"type":21,"name":15,"description":24,"armGroupLabels":25,"otherNames":10},"The patients received the concomitant administration of Bacteroides fragilis and BCAA, supplemented to their ongoing combination therapy with PegIFNα2b and Nucleoside analog.",[15],[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"JinShui Pan","CONTACT","0086+059187981658","zdy20221021@gmail.com",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"The First Affiliated Hospital of Fujian Medical University","RECRUITING","Fuzhou","Fujian","350005","China","CN",{"type":42,"coordinates":43},"Point",[44,45],119.30611,26.06139,{"lat":45,"lon":44},[48],{"name":49,"role":29,"phone":50,"phoneExt":10,"email":51},"Anpeng Wu","0086+059187981029","fjydfyjg@163.com",{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100612744","combined-use-of-bacteroides-fragilis-and-bcaas-on-hbsag-clearance-100612744",false,"NCT07257562","Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance","A Prospective Observational Study on the Effects of Concomitant Administration of Bacteroides Fragilis and Branched-Chain Amino Acids on HBsAg Clearance","Inclusion Criteria:\n\n\\- chronic hepatitis B patients\n\nExclusion Criteria:\n\n* patients with malignancies\n* patients with other liver diseases\n* pregnancy patients","ALL","18 Years",{"count":64,"type":65},40,"ESTIMATED","OBSERVATIONAL","The goal of this prospective observational study is to determine the effects of concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids on hepatitis B virus clearance. The primary question it aims to answer is whether this concomitant administration can promote HBV clearance.\n\nThe study will observe the HBV clearance rate in chronic hepatitis B patients who receive Bacteroides fragilis and BCAA as a supplement to their routine antiviral therapy. For comparison, researchers will compare the clearance rate in this group to that observed in a control group of chronic hepatitis B patients receiving a standard antiviral regimen based on PegIFNα2b and nucleoside analogs.",[69],"Chronic Hepatitis B",[71],"Hepatitis B","2025-12-01",{"date":74,"type":75},"2025-12-02","ACTUAL",{"date":77,"type":75},"2025-06-01",{"date":79,"type":65},"2026-12-01",{"name":5,"class":6},1]